EUVIMEDEUVIMED entdecken
Open Access

Association Between Cost Sharing and Naloxone Prescription Dispensing

Kao-Ping Chua, Rena M Conti, Pooja Lagisetty, Amy S Bohnert, Sijia He, Thuy D Nguyen

JAMA · 09.07.2024 · 332 (2) · 124

DOI: 10.1001/jama.2024.8378 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 09.07.2024. Verfasst von Kao-Ping Chua und 5 weiteren Autor:innen. Beteiligte Einrichtung: Susan B. Meister Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan Medical School, Ann Arbor. Hauptthemen laut MEDLINE: Cost Sharing, Drug Prescriptions, Naloxone, Narcotic Antagonists. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Increasing access to naloxone (an opioid antagonist that can reverse overdose) could slow the US opioid epidemic. Prior studies suggest cost sharing may be a barrier to dispensing of naloxone prescriptions, but these studies were limited by their cross-sectional designs and use of databases that do not capture prescriptions that are not filled (abandoned).

Objective

To evaluate the association between cost sharing and naloxone prescription abandonment (nondispensing of naloxone prescriptions). Design, Setting, and Participants This cross-sectional, regression discontinuity analysis exploited the fact that deductibles typically reset at the beginning of the year in commercial and Medicare plans. The included data were derived from the 2020-2021 IQVIA Formulary Impact Analyzer (a pharmacy transactions database that represents 63% of prescriptions at US pharmacies). The analysis included claims for naloxone nasal spray among commercially insured patients and Medicare patients that occurred during the 60 days before January 1, 2021, through 59 days after January 1, 2021. Exposure Cost sharing, which is defined as the amount patients would have to pay to fill prescriptions. Main Outcomes and Measures Local linear regression models were used to assess for abrupt changes in cost sharing and the probability of prescription abandonment on January 1, 2021. To estimate the association between cost sharing and prescription abandonment, a fuzzy regression discontinuity analysis was conducted.

Results

These analyses included naloxone claims for 71 306 commercially insured patients and 101 706 Medicare patients (40 019 [56.1%] and 61 410 [60.4%], respectively, were female). The commercially insured patients and Medicare patients accounted for 73 311 and 106 076 naloxone claims, respectively. On January 1, 2021, the mean cost sharing per claim increased by $15.0 (95% CI, $13.8-$16.2) for commercially insured patients and increased by $12.3 (95% CI, $10.9-$13.6) for Medicare patients and the probability of abandonment increased by 4.7 (95% CI, 3.2-6.2) percentage points and 2.8 (95% CI, 1.6-4.1) percentage points, respectively. The results from the fuzzy regression discontinuity analysis suggest a decision by commercial and Medicare plans to increase naloxone cost sharing by $10 would be associated with percentage-point increases of 3.1 (95% CI, 2.2-4.1) and 2.3 (95% CI, 1.4-3.2), respectively, in the probability of abandonment.

Conclusions

The elimination of cost sharing might be associated with increased naloxone dispensing to commercially insured and Medicare patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost SharingDrug PrescriptionsNaloxoneNarcotic AntagonistsOpioid-Related DisordersAdultFemaleHumansMaleMiddle AgedCross-Sectional StudiesMedicareUnited StatesInsurance, HealthDrug Monitoring

Substanzen

NaloxoneNarcotic Antagonists

Autor:innen und Institutionen

  • Susan B. Meister Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan Medical School, Ann Arbor.
  • Department of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor.
  • Department of Markets, Public Policy, and Law, Questrom School of Business, Boston University, Boston, Massachusetts.
  • Department of Medicine, University of Michigan Medical School, Ann Arbor.
  • Department of Anesthesiology, University of Michigan Medical School, Ann Arbor.

Förderung

  • NIDA NIH HHS

Zitieren

APA

Chua, K. P., Conti, R. M., Lagisetty, P., Bohnert, A. S., He, S., & Nguyen, T. D. (2024). Association Between Cost Sharing and Naloxone Prescription Dispensing. JAMA, 332(2), 124. https://doi.org/10.1001/jama.2024.8378

Vancouver

Chua KP, Conti RM, Lagisetty P, Bohnert AS, He S, Nguyen TD. Association Between Cost Sharing and Naloxone Prescription Dispensing. JAMA. 2024;332(2):124. doi:10.1001/jama.2024.8378

BibTeX
@article{Chua2024,
  author = {Chua, Kao-Ping and Conti, Rena M and Lagisetty, Pooja and Bohnert, Amy S and He, Sijia and Nguyen, Thuy D},
  title = {Association Between Cost Sharing and Naloxone Prescription Dispensing},
  journal = {JAMA},
  year = {2024},
  volume = {332},
  number = {2},
  pages = {124},
  doi = {10.1001/jama.2024.8378}
}
Kostenlos starten →